Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 14

1.

Preoperative FDG-PET/CT Is an Important Tool in the Management of Patients with Thick (T4) Melanoma.

Arrangoiz R, Papavasiliou P, Stransky CA, Yu JQ, Tianyu L, Sigurdson ER, Berger AC, Farma JM.

Dermatol Res Pract. 2012;2012:614349. doi: 10.1155/2012/614349. Epub 2012 May 13.

2.

Incidental PET/CT findings in the cancer patient: how should they be managed?

Beatty JS, Williams HT, Aldridge BA, Hughes MP, Vasudeva VS, Gucwa AL, David GS, Lind DS, Kruse EJ, McLoughlin JM.

Surgery. 2009 Aug;146(2):274-81. doi: 10.1016/j.surg.2009.04.024.

PMID:
19628085
3.

High-grade endometrial cancer: value of [(18)F]FDG PET/CT in preoperative staging.

Picchio M, Mangili G, Samanes Gajate AM, De Marzi P, Spinapolice EG, Mapelli P, Giovacchini G, Sigismondi C, Viganò R, Sironi S, Messa C.

Nucl Med Commun. 2010 Jun;31(6):506-12. doi: 10.1097/MNM.0b013e328337cb47.

PMID:
20168262
4.

Prospective comparison of [18F]fluorodeoxyglucose positron emission tomography and computed tomography in patients with melanoma with palpable lymph node metastases: diagnostic accuracy and impact on treatment.

Bastiaannet E, Wobbes T, Hoekstra OS, van der Jagt EJ, Brouwers AH, Koelemij R, de Klerk JM, Oyen WJ, Meijer S, Hoekstra HJ.

J Clin Oncol. 2009 Oct 1;27(28):4774-80. doi: 10.1200/JCO.2008.20.1822. Epub 2009 Aug 31.

PMID:
19720925
6.
7.

Interpretation, accuracy and management implications of FDG PET/CT in cutaneous malignant melanoma.

Falk MS, Truitt AK, Coakley FV, Kashani-Sabet M, Hawkins RA, Franc B.

Nucl Med Commun. 2007 Apr;28(4):273-80.

PMID:
17325590
8.

Is there an added clinical value of "true"whole body(18)F-FDG PET/CT imaging in patients with malignant melanoma?

Tan JC, Chatterton BE.

Hell J Nucl Med. 2012 Sep-Dec;15(3):202-5. doi: 10.1967/s002449910055. Epub 2012 Oct 25.

PMID:
23106051
9.

A prospective diagnostic accuracy study of 18F-fluorodeoxyglucose positron emission tomography/computed tomography, multidetector row computed tomography, and magnetic resonance imaging in primary diagnosis and staging of pancreatic cancer.

Kauhanen SP, Komar G, Seppänen MP, Dean KI, Minn HR, Kajander SA, Rinta-Kiikka I, Alanen K, Borra RJ, Puolakkainen PA, Nuutila P, Ovaska JT.

Ann Surg. 2009 Dec;250(6):957-63. doi: 10.1097/SLA.0b013e3181b2fafa.

PMID:
19687736
10.

The impact of 18F-FDG PET/CT in patients with liver metastases.

Chua SC, Groves AM, Kayani I, Menezes L, Gacinovic S, Du Y, Bomanji JB, Ell PJ.

Eur J Nucl Med Mol Imaging. 2007 Dec;34(12):1906-14. Epub 2007 Aug 23.

PMID:
17713766
11.

Performance of FDG PET/CT in postoperative colorectal cancer patients with a suspected recurrence and a normal CEA level.

Lee JH, Park SG, Jee KN, Park DG, Namgung H, Song IH.

Nucl Med Commun. 2010 Jun;31(6):576-82. doi: 10.1097/MNM.0b013e32833845b7.

PMID:
20216474
12.

The value of 18F-DOPA PET-CT in patients with medullary thyroid carcinoma: comparison with 18F-FDG PET-CT.

Beheshti M, Pöcher S, Vali R, Waldenberger P, Broinger G, Nader M, Kohlfürst S, Pirich C, Dralle H, Langsteger W.

Eur Radiol. 2009 Jun;19(6):1425-34. doi: 10.1007/s00330-008-1280-7. Epub 2009 Jan 21.

PMID:
19156423
13.

Delayed response assessment with FDG-PET-CT following (chemo) radiotherapy for locally advanced head and neck squamous cell carcinoma.

Prestwich RJ, Subesinghe M, Gilbert A, Chowdhury FU, Sen M, Scarsbrook AF.

Clin Radiol. 2012 Oct;67(10):966-75. doi: 10.1016/j.crad.2012.02.016. Epub 2012 May 15.

PMID:
22595082
14.

Minimal-activity/low-dose PET/CT-a problem-solving tool for uncertain pulmonary PET findings without correlative CT lesions.

Gühne F, Drescher R, Freesmeyer M.

Jpn J Clin Oncol. 2017 Mar 8:1-2. doi: 10.1093/jjco/hyx036. [Epub ahead of print] No abstract available.

PMID:
28334894

Supplemental Content

Support Center